Trial Outcomes & Findings for PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy (NCT NCT00364013)

NCT ID: NCT00364013

Last Updated: 2022-11-07

Results Overview

Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

• Recruitment status: COMPLETED
• Study phase: PHASE3
• Target enrollment: 1183 participants
• Primary outcome timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.
• Results posted on: 2022-11-07

Participant Flow

First patient enrolled 23 August 2006 and last patient enrolled 01 February 2008. Participant flow data are reported as of the data cut-off date of 28 August 2009.

Participant milestones

Measure	FOLFOX + Panitumumab Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	FOLFOX Alone Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Overall Study STARTED	593	590
Overall Study Received Study Drug	586	583
Overall Study COMPLETED	492	495
Overall Study NOT COMPLETED	101	95

Reasons for withdrawal

Measure	FOLFOX + Panitumumab Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	FOLFOX Alone Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Overall Study Ineligibility determined	4	2
Overall Study Adverse Event	4	3
Overall Study Withdrawal by Subject	13	18
Overall Study Physician Decision	3	3
Overall Study Lost to Follow-up	10	3
Overall Study Protocol-specified criteria	6	6
Overall Study Other	41	47
Overall Study Ongoing	20	13

Baseline Characteristics

PRIME: Panitumumab Randomized Trial In Combination With Chemotherapy for Metastatic Colorectal Cancer to Determine Efficacy

Baseline characteristics by cohort

Measure	FOLFOX + Panitumumab n=593 Participants Participants were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	FOLFOX Alone n=590 Participants Participants were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Total n=1183 Participants Total of all reporting groups
Age, Continuous	61.5 years STANDARD_DEVIATION 10.1 • n=5 Participants	60.3 years STANDARD_DEVIATION 11.0 • n=7 Participants	60.9 years STANDARD_DEVIATION 10.6 • n=5 Participants
Sex: Female, Male Female	207 Participants n=5 Participants	232 Participants n=7 Participants	439 Participants n=5 Participants
Sex: Female, Male Male	386 Participants n=5 Participants	358 Participants n=7 Participants	744 Participants n=5 Participants
Race/Ethnicity, Customized White or Caucasian	530 participants n=5 Participants	540 participants n=7 Participants	1070 participants n=5 Participants
Race/Ethnicity, Customized Black or African American	8 participants n=5 Participants	15 participants n=7 Participants	23 participants n=5 Participants
Race/Ethnicity, Customized Hispanic or Latino	42 participants n=5 Participants	26 participants n=7 Participants	68 participants n=5 Participants
Race/Ethnicity, Customized Asian	8 participants n=5 Participants	4 participants n=7 Participants	12 participants n=5 Participants
Race/Ethnicity, Customized Other	5 participants n=5 Participants	5 participants n=7 Participants	10 participants n=5 Participants
Geographic Region Western Europe, Canada and Australia	332 participants n=5 Participants	329 participants n=7 Participants	661 participants n=5 Participants
Geographic Region Rest of world	261 participants n=5 Participants	261 participants n=7 Participants	522 participants n=5 Participants
KRAS Status Wild-type KRAS	325 participants n=5 Participants	331 participants n=7 Participants	656 participants n=5 Participants
KRAS Status Mutant KRAS	221 participants n=5 Participants	219 participants n=7 Participants	440 participants n=5 Participants
KRAS Status Unevaluable KRAS	47 participants n=5 Participants	40 participants n=7 Participants	87 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 0	332 participants n=5 Participants	320 participants n=7 Participants	652 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 1	230 participants n=5 Participants	238 participants n=7 Participants	468 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 2	31 participants n=5 Participants	29 participants n=7 Participants	60 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 3	0 participants n=5 Participants	0 participants n=7 Participants	0 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Grade 4	0 participants n=5 Participants	1 participants n=7 Participants	1 participants n=5 Participants
Eastern Cooperative Oncology Group (ECOG) Performance Status Mising/Unknown	0 participants n=5 Participants	2 participants n=7 Participants	2 participants n=5 Participants
Primary tumor type Colon cancer	394 participants n=5 Participants	398 participants n=7 Participants	792 participants n=5 Participants
Primary tumor type Rectal cancer	199 participants n=5 Participants	192 participants n=7 Participants	391 participants n=5 Participants

PRIMARY outcome

Timeframe: From randomization until the data cutoff date of 30 September 2008. Maximum follow-up time was 109 weeks.

Population: KRAS Efficacy Analysis Set (participants for whom KRAS status was assessed)

Progression-free survival (PFS), assessed by central radiological assessment, was defined as the time from randomization to disease progression per modified response evaluation criteria in solid tumors (RECIST) criteria or death. Participants who were alive but did not meet criteria for progression by the data cutoff date were censored at their last evaluable disease assessment date. Progressive disease is defined as a ≥ 20% increase in the size of target lesions or unequivocal progression of existing non-target lesions or any new lesions.

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=325 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=331 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab n=221 Participants Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX n=219 Participants Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Progression-free Survival	9.6 months Interval 9.2 to 11.1	8.0 months Interval 7.5 to 9.3	7.3 months Interval 6.3 to 8.0	8.8 months Interval 7.7 to 9.4

SECONDARY outcome

Timeframe: From randomization until the data cutoff date of 28 August 2009. Maximum time on follow-up was 153 weeks.

Population: KRAS Efficacy Analysis Set

The definition of overall survival is the time from randomization to death; participants who were alive at the analysis data cutoff were censored at their last contact date.

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=325 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=331 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab n=221 Participants Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX n=219 Participants Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Overall Survival	23.9 months Interval 20.3 to 28.3	19.7 months Interval 17.6 to 22.6	15.5 months Interval 13.1 to 17.6	19.3 months Interval 16.5 to 21.8

SECONDARY outcome

Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Population: KRAS Evaluable Central Tumor Response Analysis Set (subset of participants with at least one uni-dimensionally measurable lesion per the modified RECIST criteria per blinded central radiology review).

Participants were evaluated for tumor response per the modified Response Evaluation Criteria in Solid Tumors (RECIST) criteria every 8 weeks until disease progression. Objective response by central radiological assessment was defined as the incidence of either a confirmed complete or partial response (CR or PR) while on the first-line treatment, as determined by blinded independent central review and confirmed no less than 4-weeks after the criteria for response are first met. CR: Disappearance of all target and non-target lesions and no new lesions. PR: At least a 30% decrease in the sum of the longest diameter of target lesions and no progression of non-target or no new lesions, or, disappearance of all target lesions and the persistence of ≥ 1 non-target lesion not qualifying for either CR or progressive disease. Participants without a post-baseline assessment were considered non-responders.

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=317 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=323 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab n=215 Participants Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX n=211 Participants Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Percentage of Participants With an Objective Response	55.21 percentage of participants Interval 49.55 to 60.77	47.68 percentage of participants Interval 42.12 to 53.28	39.53 percentage of participants Interval 32.95 to 46.41	40.28 percentage of participants Interval 33.61 to 47.24

SECONDARY outcome

Timeframe: From randomization until the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Population: KRAS Efficacy Analysis Set

Time to progression was defined as time from randomization date to date of disease progression per the modified RECIST criteria.

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=325 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=331 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab n=221 Participants Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX n=219 Participants Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Time to Progression	10.8 months Interval 9.4 to 12.4	9.2 months Interval 7.7 to 9.9	7.5 months Interval 7.2 to 8.9	9.0 months Interval 7.7 to 9.5

SECONDARY outcome

Timeframe: Every 8 weeks until disease progression up to the data cut-off date of 30 September 2008; Maximum follow-up time was 109 weeks.

Population: KRAS Evaluable Central Tumor Response Analysis Set: Responders

Duration of response was calculated only for those participants with a confirmed CR or PR, as the time from the first CR or PR (subsequently confirmed within no less than 4 weeks) to first observed disease progression per modified RECIST criteria, based on a blinded central review.

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=175 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=154 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab n=85 Participants Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX n=85 Participants Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Duration of Response	11.1 months Interval 9.5 to 13.0	8.8 months Interval 7.8 to 9.7	7.4 months Interval 5.9 to 8.3	8.0 months Interval 6.5 to 9.5

SECONDARY outcome

Timeframe: From randomization until the data cut-off date of 28 August 2009; Maximum time on follow-up was 153 weeks.

Population: Safety analysis set; One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group.

A serious adverse event (SAE) is defined as an AE that • is fatal • is life threatening • requires in-patient hospitalization or prolongation of existing hospitalization • results in persistent or significant disability/incapacity • is a congenital anomaly/birth defect • other significant medical hazard. The relationship of the adverse event to the study treatment was assessed by the Investigator by means of the question: "Is there a reasonable possibility that the event may have been caused by the study treatment?"

Outcome measures

Measure	Wild-type KRAS - FOLFOX + Panitumumab n=585 Participants Participants with wild-type KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Wild-type KRAS - FOLFOX n=584 Participants Participants with wild-type KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.	Mutant KRAS - FOLFOX + Panitumumab Participants with mutant KRAS were randomized to panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	Mutant KRAS - FOLFOX Participants with mutant KRAS were randomized to FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Number of Participants With Adverse Events (AEs) Any adverse event	583 participants	579 participants	—	—
Number of Participants With Adverse Events (AEs) Serious adverse event	262 participants	198 participants	—	—
Number of Participants With Adverse Events (AEs) Leading to discontinuation of any study drug	136 participants	84 participants	—	—
Number of Participants With Adverse Events (AEs) Treatment-related adverse event (TRAE)	581 participants	565 participants	—	—
Number of Participants With Adverse Events (AEs) Serious treatment-related adverse event	162 participants	89 participants	—	—
Number of Participants With Adverse Events (AEs) TRAE leading to discontinuation of any study drug	117 participants	63 participants	—	—

Adverse Events

Panitumumab Plus FOLFOX

Serious events: 262 serious events

Other events: 577 other events

Deaths: 0 deaths

FOLFOX Alone

Serious events: 198 serious events

Other events: 571 other events

Deaths: 0 deaths

Serious adverse events

Measure	Panitumumab Plus FOLFOX n=585 participants at risk Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	FOLFOX Alone n=584 participants at risk Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Blood and lymphatic system disorders Anaemia	1.4% 8/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Febrile neutropenia	2.6% 15/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.4% 14/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Hyperviscosity syndrome	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Idiopathic thrombocytopenic purpura	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Leukopenia	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Neutropenia	1.9% 11/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.7% 10/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Splenic lesion	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Thrombocytopenia	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Acute myocardial infarction	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Angina pectoris	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Angina unstable	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Atrial fibrillation	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Cardiac failure congestive	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Cardio-respiratory arrest	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Cardiogenic shock	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Myocardial infarction	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Myocardial ischaemia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Tachycardia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Ventricular arrhythmia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Cardiac disorders Ventricular fibrillation	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Congenital, familial and genetic disorders Gilbert's syndrome	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Ear and labyrinth disorders Vertigo	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Eye disorders Amaurosis fugax	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Eye disorders Conjunctivitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Eye disorders Trichiasis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Abdominal pain	2.4% 14/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.7% 10/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Abdominal pain upper	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Anal erosion	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Anal fistula	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Anal haemorrhage	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Anorectal disorder	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Ascites	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Colonic obstruction	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Colonic stenosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Constipation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Dental caries	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Diarrhoea	9.9% 58/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.9% 17/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Dry mouth	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Dysphagia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Enterovesical fistula	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Faecal incontinence	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Faecalith	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Gastric dilatation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Gastric haemorrhage	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Gastrointestinal haemorrhage	0.85% 5/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Gastrointestinal inflammation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Gastrointestinal perforation	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Haematemesis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Haemorrhoidal haemorrhage	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Haemorrhoids	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Ileus	1.0% 6/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Inguinal hernia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Intestinal ischaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Intestinal obstruction	3.1% 18/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.1% 12/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Intestinal perforation	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Intestinal prolapse	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Intra-abdominal haemorrhage	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Large intestinal obstruction	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Large intestine perforation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Mechanical ileus	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Melaena	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Nausea	2.1% 12/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Obstruction gastric	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Oesophagitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Peritonitis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Rectal haemorrhage	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Rectal perforation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Retroperitoneal oedema	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Small intestinal obstruction	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.86% 5/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Stomatitis	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Subileus	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Upper gastrointestinal haemorrhage	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Vomiting	3.1% 18/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.1% 12/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Asthenia	1.0% 6/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Catheter related complication	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Catheter site haemorrhage	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Catheter thrombosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Chest pain	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Chills	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Fatigue	0.85% 5/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders General physical health deterioration	1.2% 7/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Hyperpyrexia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Inflammation of wound	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Infusion site extravasation	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Malaise	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Mucosal inflammation	1.0% 6/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Multi-organ failure	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Oedema	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Oedema peripheral	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Pelvic mass	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Performance status decreased	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Pyrexia	2.7% 16/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.6% 15/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Sudden death	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Bile duct obstruction	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Bile duct stone	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Cholangitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Cholecystitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Cholecystitis acute	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Cholelithiasis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Cholestasis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Hepatic failure	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Hyperbilirubinaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Jaundice	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Hepatobiliary disorders Portal vein thrombosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Immune system disorders Drug hypersensitivity	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Immune system disorders Hypersensitivity	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.68% 4/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Abdominal abscess	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Abdominal sepsis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Abdominal wall abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Abscess intestinal	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Acne pustular	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Anal abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Bacteraemia	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Biliary abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Biliary sepsis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Bronchitis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Bronchopneumonia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Catheter related infection	1.0% 6/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.68% 4/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Catheter sepsis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Cellulitis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Central line infection	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Conjunctivitis infective	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Cystitis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Diabetic gangrene	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Folliculitis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Gastroenteritis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Groin abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Hepatic infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Herpes zoster	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Liver abscess	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Lobar pneumonia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Lower respiratory tract infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Lung abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Lung infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Necrotising fasciitis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Neutropenic sepsis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Oral herpes	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Orchitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Pneumonia	1.7% 10/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.4% 8/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Pneumonia bacterial	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Pneumonia mycoplasmal	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Post procedural infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Postoperative wound infection	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Pseudomonal sepsis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Pyelonephritis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Respiratory tract infection	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Salmonellosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Sepsis	2.1% 12/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.2% 7/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Septic shock	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Skin infection	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Staphylococcal infection	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Subcutaneous abscess	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Subdiaphragmatic abscess	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Tooth infection	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Upper respiratory tract infection	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Urinary tract infection	1.2% 7/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.86% 5/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Urinary tract infection viral	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Viral infection	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Anal injury	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Anastomotic leak	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Device dislocation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Fall	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Femur fracture	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Gastrointestinal stoma complication	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Hepatic haematoma	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Hip fracture	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Medical device complication	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Post procedural complication	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Procedural pain	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Road traffic accident	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Skin laceration	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Spinal fracture	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Stent occlusion	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Transfusion reaction	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Injury, poisoning and procedural complications Upper limb fracture	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Fluid overload	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Investigations Blood creatinine increased	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Investigations Blood culture positive	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Investigations Cardiac enzymes increased	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Investigations Weight decreased	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Anorexia	1.5% 9/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Dehydration	3.4% 20/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.86% 5/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypercalcaemia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Diabetes mellitus	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Diabetes mellitus inadequate control	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Diabetic ketoacidosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Failure to thrive	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hyperglycaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypoalbuminaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypocalcaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypoglycaemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypokalaemia	1.0% 6/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypomagnesaemia	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hyponatraemia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Ketoacidosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Back pain	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Musculoskeletal pain	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Neck pain	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Osteoporotic fracture	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Pain in extremity	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Rotator cuff syndrome	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Bone neoplasm	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Cancer pain	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Colorectal cancer metastatic	1.5% 9/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.86% 5/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to bone	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to central nervous system	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastases to ovary	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Metastatic neoplasm	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Pelvic neoplasm	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Prostate cancer	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour associated fever	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour haemorrhage	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Neoplasms benign, malignant and unspecified (incl cysts and polyps) Tumour local invasion	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Aphasia	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Ataxia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Balance disorder	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Cerebral haemorrhage	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Cerebral infarction	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Cerebral ischaemia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Cerebrovascular accident	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Cerebrovascular insufficiency	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Coma	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Convulsion	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Dysarthria	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Hemiparesis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Hydrocephalus	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Ischaemic stroke	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Lethargy	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Mental impairment	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Nervous system disorder	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Neuropathy peripheral	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Paraparesis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Spinal cord compression	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Syncope	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Transient ischaemic attack	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Abnormal behaviour	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Confusional state	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Personality disorder	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Calculus ureteric	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Oliguria	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Renal colic	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Renal failure	1.4% 8/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.0% 6/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Renal failure acute	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Urinary bladder haemorrhage	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Renal and urinary disorders Urinary retention	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Acute pulmonary oedema	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Acute respiratory distress syndrome	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Allergic cough	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Aspiration	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Dyspnoea	0.85% 5/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Epistaxis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Haemoptysis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Hypoxia	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Interstitial lung disease	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Laryngospasm	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Oropharyngeal pain	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pleural effusion	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pneumonitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pneumothorax	0.51% 3/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.51% 3/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary artery thrombosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary embolism	2.4% 14/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.7% 10/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary fibrosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary infarction	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Pulmonary thrombosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Respiratory arrest	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Respiratory failure	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Wheezing	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Acne	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Dermatitis acneiform	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Dermatitis allergic	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Dermatosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Hyperhidrosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Pruritus allergic	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Rash	1.7% 10/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Rash pruritic	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Skin exfoliation	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Skin toxicity	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Swelling face	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Toxic skin eruption	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Surgical and medical procedures Catheter placement	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Arterial thrombosis limb	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Axillary vein thrombosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Circulatory collapse	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Deep vein thrombosis	1.5% 9/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.86% 5/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Embolism	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Embolism venous	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Hypotension	0.68% 4/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Iliac artery embolism	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Peripheral embolism	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Subclavian vein thrombosis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Thrombophlebitis	0.17% 1/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Thrombosis	0.00% 0/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Venous thrombosis	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Venous thrombosis limb	0.34% 2/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.17% 1/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.

Other adverse events

Measure	Panitumumab Plus FOLFOX n=585 participants at risk Participants received panitumumab, 6 mg/kg on Day 1 and FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or unacceptable toxicity.	FOLFOX Alone n=584 participants at risk Participants received FOLFOX chemotherapy regimen on Days 1 and 2 of each 14-day cycle until disease progression or until unacceptable toxicity.
Blood and lymphatic system disorders Anaemia	14.4% 84/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	13.9% 81/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Leukopenia	8.2% 48/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	8.6% 50/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Neutropenia	53.8% 315/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	60.4% 353/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Blood and lymphatic system disorders Thrombocytopenia	19.7% 115/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	26.9% 157/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Eye disorders Conjunctivitis	17.6% 103/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	3.4% 20/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Eye disorders Lacrimation increased	4.4% 26/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.8% 40/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Abdominal pain	26.7% 156/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	22.8% 133/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Abdominal pain upper	8.4% 49/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	9.4% 55/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Constipation	26.3% 154/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	26.5% 155/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Diarrhoea	59.7% 349/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	48.3% 282/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Dry mouth	5.3% 31/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	2.9% 17/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Dyspepsia	10.9% 64/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	10.8% 63/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Nausea	44.6% 261/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	49.1% 287/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Stomatitis	23.6% 138/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	13.2% 77/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Gastrointestinal disorders Vomiting	29.9% 175/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	31.2% 182/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Asthenia	22.6% 132/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	20.0% 117/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Fatigue	34.0% 199/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	33.7% 197/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Mucosal inflammation	24.4% 143/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	14.9% 87/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Oedema peripheral	10.4% 61/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	8.0% 47/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
General disorders Pyrexia	29.1% 170/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	25.5% 149/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Nasopharyngitis	5.3% 31/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	4.3% 25/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Paronychia	20.5% 120/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.00% 0/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Infections and infestations Urinary tract infection	6.0% 35/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	5.3% 31/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Investigations Weight decreased	16.6% 97/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.7% 39/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Anorexia	34.0% 199/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	22.8% 133/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Dehydration	5.5% 32/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.4% 8/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypocalcaemia	5.1% 30/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.9% 11/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypokalaemia	19.8% 116/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	12.5% 73/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Metabolism and nutrition disorders Hypomagnesaemia	29.9% 175/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.7% 39/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Back pain	11.5% 67/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	11.6% 68/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Musculoskeletal and connective tissue disorders Pain in extremity	7.5% 44/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.7% 39/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Dizziness	6.5% 38/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.7% 39/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Dysaesthesia	5.6% 33/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	8.6% 50/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Dysgeusia	13.2% 77/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	13.5% 79/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Headache	6.3% 37/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	12.3% 72/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Lethargy	4.1% 24/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	5.1% 30/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Neuropathy peripheral	18.8% 110/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	23.6% 138/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Paraesthesia	30.8% 180/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	34.9% 204/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Nervous system disorders Peripheral sensory neuropathy	13.2% 77/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	15.2% 89/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Anxiety	7.5% 44/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	5.3% 31/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Depression	5.8% 34/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	4.3% 25/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Psychiatric disorders Insomnia	13.7% 80/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	14.0% 82/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Cough	9.2% 54/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	14.4% 84/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Dyspnoea	8.5% 50/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.8% 40/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Respiratory, thoracic and mediastinal disorders Epistaxis	13.5% 79/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	9.1% 53/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Acne	12.6% 74/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Alopecia	13.7% 80/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	9.6% 56/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Dermatitis acneiform	32.1% 188/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Dry skin	20.5% 120/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	3.4% 20/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Erythema	16.1% 94/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	3.8% 22/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Nail disorder	8.4% 49/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	1.9% 11/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Palmar-plantar erythrodysaesthesia syndrome	9.4% 55/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	3.6% 21/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Pruritus	21.9% 128/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	4.5% 26/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Rash	52.1% 305/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.7% 39/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Skin and subcutaneous tissue disorders Skin fissures	15.2% 89/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	0.34% 2/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.
Vascular disorders Hypertension	4.4% 26/585 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.	6.2% 36/584 • The median treatment period was around 7.7 months in the Panitumumab arm, and around 6.7 months in the Chemo alone arm. One participant was randomized to 'Panitumumab Plus FOLFOX', but received 'FOLFOX Alone' so is counted in that group. The table of Other Adverse Events summarizes non-serious occurrences of adverse events that exceeded a 5% frequency threshold in either treatment group.

Additional Information

Study Director

Amgen Inc.

Phone: 866-572-6436

Results disclosure agreements

• Principal investigator is a sponsor employee The Clinical Trial Agreement generally does not restrict an investigator's discussion of trial results aftercompletion. The Agreement permits Amgen a limited period of time to review material discussing trial results (typically up to 45 days and possible extension). Amgen may remove confidential information, but authors have final control and approval of publication content. For multicenter studies, the investigator agrees not to publish any results before the first multi-center publication.
• Publication restrictions are in place

Restriction type: OTHER